World Heart (WHRT) Ends Efforts to Commercialize Levacor; Cutting 21 Jobs
World Heart (Nasdaq: WHRT) to end its efforts to commercialize levacor; to focus resources on MiFlow mini-VAD. The company will be reducing its workforce by 21 jobs, adding restructuring charges of about $3-$5 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
Create E-mail Alert Related Categories
Corporate News, FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
